AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.660
-0.170 (-6.01%)
At close: Sep 24, 2026, 4:00 PM EDT
2.450
-0.210 (-7.89%)
Pre-market: Sep 25, 2026, 4:00 AM EDT
AC Immune Revenue
AC Immune had revenue of 15.11M CHF in the quarter ending June 30, 2026, with 1,057.20% growth. This brings the company's revenue in the last twelve months to 17.51M, down -39.45% year-over-year. In the year 2025, AC Immune had annual revenue of 3.57M, down -86.92%.
Revenue (ttm)
17.51M CHF
Revenue Growth
-39.45%
P/S Ratio
12.20
Revenue / Employee
143,516 CHF
Employees
122
Market Cap
264.48M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57M | -23.74M | -86.92% |
| Dec 31, 2024 | 27.31M | 12.51M | 84.51% |
| Dec 31, 2023 | 14.80M | 10.87M | 276.14% |
| Dec 31, 2022 | 3.94M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 15.43M | -95.03M | -86.03% |
| Dec 31, 2019 | 110.46M | 103.26M | 1,435.39% |
| Dec 31, 2018 | 7.19M | -13.06M | -64.48% |
| Dec 31, 2017 | 20.26M | -2.96M | -12.75% |
| Dec 31, 2016 | 23.21M | -15.88M | -40.61% |
| Dec 31, 2015 | 39.09M | 8.82M | 29.14% |
| Dec 31, 2014 | 30.27M | 21.63M | 250.46% |
| Dec 31, 2013 | 8.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Bicycle Therapeutics | 61.21M |
| Invivyd | 58.37M |
| Sutro Biopharma | 45.70M |
| ProQR Therapeutics | 21.05M |
| Lineage Cell Therapeutics | 13.08M |
| Pyxis Oncology | 11.04M |
| Camp4 Therapeutics | 4.22M |
ACIU News
- 1 day ago - AC Immune Transcript: Study result - Transcripts
- 1 day ago - AC Immune Press release: Study result - Filings
- 1 day ago - AC Immune Slides: Study result - Filings
- 1 day ago - AC Immune announces Phase 2 trial of ACI-7104 met primary endpoints - TheFly
- 2 days ago - AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - GlobeNewsWire
- 4 weeks ago - AC Immune Slides: Investor presentation - Filings
- 5 weeks ago - AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - GlobeNewsWire
- 6 weeks ago - AC Immune receives fast track designation, clearance for ACI-7104 IND - TheFly